Deal snapshot: TAPLMMUNE, MARKER THERAPEUTICS CLOSE MERGER OF EQUALS TRANSACTION.

MANews-(C)2009-2018

Florida, US-based immuno-oncology company TapImmune Inc. (NASDAQ: TPIV) has closed the acquisition of Minnesota, US-based Marker Therapeutics, Inc. a clinical-stage developer of a non-genetically engineered, multi-antigen T cell therapy platform, the company said.

The proposed transaction is a merger-of-equals under which the stockholders of TapImmune and Marker will each own approximately 50% of the combined company, prior to any issuances of additional shares in a contemplated financing.

Country: USA

Sector: Pharmaceuticals

Target: Marker Therapeutics

Buyer...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT